Monitor for any strategic shifts under new Chairman Scott Garland, but the orderly transition and lack of disagreement suggest continuity. The appointment of a seasoned General Counsel signals preparation for late-stage development and potential partnerships.
Price Chart
Executive Summary
ALX Oncology announced the resignation of co-founder and Chairman Corey Goodman, Ph.D., effective June 29, 2026, for personal reasons with no disagreement. Scott Garland, an independent director since November 2022, was appointed as Chairman, and Michael Listgarten was appointed as General Counsel. This is a routine governance transition with no financial or operational changes disclosed.
Key Facts
- Corey Goodman, Ph.D., resigned as Chairman and board member effective June 29, 2026, citing personal reasons and no disagreement with the company.
- Scott Garland, an independent director since November 2022, was appointed Chairman of the Board.
- Michael Listgarten was appointed General Counsel, effective immediately.
- Board committees were reconstituted: Audit Committee (Rekha Hemrajani Chair), Compensation Committee (Chris Takimoto Chair), Corporate Governance and Nominating Committee (Daniel J. Curran Chair).
Financial Impact
No financial impact disclosed; routine governance change.
Risk Factors
- Loss of co-founder leadership may affect long-term strategic vision and investor confidence.
- No immediate operational changes, but future board decisions could shift pipeline priorities.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290447 |
| Document: alxo-ex99_1.htm | 0001193125-26-290447 |
| Document: 0001193125-26-290447-index-headers.html | 0001193125-26-290447 |
| Document: 0001193125-26-290447-index.html | 0001193125-26-290447 |
| Document: 0001193125-26-290447.txt | 0001193125-26-290447 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | SC 13D/A | $1.14 $1.13 | ▼ −0.88% | ▼ −0.73% | $1.13 (−0.88%) |
Oct 15, 2026 11d ago | 8-K | $1.06 $1.17 | ▲ +10.38% | ▲ +10.81% | $1.13 (+6.60%) |
Sep 28, 2026 28d ago | Press Release | $1.39 $1.21 | ▼ −12.95% | ▼ −14.15% | $1.13 (−18.71%) |
Aug 15, 2026 10w ago | Institutional Cluster | $1.97 $1.99 | ▲ +1.02% | ▲ +2.21% | $1.13 (−42.64%) |
Aug 6, 2026 11w ago | 8-K | $2.11 $1.94 | ▼ −8.06% | ▼ −9.27% | $1.13 (−46.45%) |
Jun 30, 2026 16w ago | 8-K | $2.06 $2.36 | ▲ +14.56% | ▲ +14.30% | $1.13 (−45.15%) |
Jun 26, 2026 17w ago | 8-K | $2.20 $2.19 | ▼ −0.45% | ▼ −1.84% | $1.13 (−48.64%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.58 $1.53 | ▲ +3.16% | ▲ +3.84% | $1.13 (+28.48%) |
May 8, 2026 24w ago | 8-K | $2.08 $2.04 | ▼ −1.92% | ▼ −3.39% | $1.13 (−45.67%) |
May 8, 2026 24w ago | Press Release | $2.08 $2.04 | ▲ +1.92% | ▲ +3.39% | $1.13 (+45.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers